Licensing & partnership
Blackstone commits up to $1.5 billion toward Pfizer's monthly GLP-1 berobenatide
Funds managed by Blackstone will pay as much as $1.5 billion by 2028 toward development of berobenatide, Pfizer's investigational once-a-month GLP-1 agonist. Blackstone earns payments only if the drug wins US approval for chronic weight management and meets sales targets, while Pfizer keeps ownership and control. Pfizer has 10 phase 3 trials under way or planned.
- Drugberobenatide
- CompanyPfizer
- CompanyBlackstone
- CompanyBlackstone Life Sciences
- TargetGlucagon-like peptide-1 receptor
Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.